If you only glanced at AbCellera Biologics during this stretch, the headlines might have felt mixed. For AbCellera Biologics shareholders, the return over the past year was 124.8%, including dividends. That surge arrived alongside revenue that moved from US$17.084 million in Q2 2025 to US$4.05 million in Q2 2026 and a wider quarterly loss. If you had been deciding back in October 2025, you might have asked what mattered more: the clinical and partnership story, or the financial hit.
Narratives are how investors here put a case on the record, with explicit assumptions about revenue, margins and the multiple. Those assumptions imply an estimated Fair Value.
This theme extends beyond AbCellera Biologics. See which of 33 healthcare AI stocks may still merit a closer look.
The Two AbCellera Biologics Stories Investors Were Arguing Over
The shares cost US$5.53 at the start of the period, so anyone looking at AbCellera Biologics then had to pick a side on what might happen next.
The bullish narrative put Fair Value at US$9.22, based on the idea that moving ABCL635 and ABCL575 into Phase I and finishing integrated clinical manufacturing by the end of 2025 could support future milestone fees and royalties.
The bearish view set Fair Value at US$5 and focused on execution and regulatory risk, assuming 12.4% revenue growth but warning that dependence on milestones, royalties and heavy R&D spending could keep results volatile.
What The Evidence Around AbCellera Biologics Actually Tested
The key development for AbCellera Biologics was ABCL635 moving through Phase 1 with positive safety and target engagement, then into Phase 2 with top-line data meeting efficacy goals. That outcome supported the bullish focus on the internal pipeline. By contrast, revenue slipped from US$17.084 million in Q2 2025 to US$4.05 million in Q2 2026 and the quarterly loss widened, so profitability assumptions stayed unproven. Overall, the evidence cut both ways.
The lesson is simple. When a story hangs on pipeline transition, track two lines separately. Check clinical milestones against guidance, and compare revenue and net income to see whether the financial side is catching up or just funding the science.
What AbCellera Biologics' 125% Run-Up Now Asks You To Believe
AbCellera Biologics now trades at US$12.63, after a 124.8% gain over the past year. The selected Narrative places Fair Value above that level, hinging on ABCL635 menopause data, new deals and a shift toward milestone- and royalty-driven income.
In that view, today’s price still does not fully credit ABCL635’s commercial potential and the long-term revenue impact of recent partnerships.
"AbCellera's transition from a platform company to a clinical-stage biotech, along with the development of internal programs, suggests a shift towards generating revenue from downstream milestone fees and royalty payments as new molecules are expected to reach the clinic."
The price and this Narrative do not agree. → Uncover what this Narrative says AbCellera Biologics is actually worth
Which Company Could Surprise You Next?
What if your next investment idea came before the headlines? Go straight to the companies whose prices and our estimates still disagree. Three places to start, with the names waiting behind the link.
- Company 1 - 17% below our estimate - targets buyers rushing to deploy GPU server racks amid supply uncertainty.
- Company 2 - 43% below our estimate - builds large transport hubs and defense projects supported by long-term contracts.
- Company 3 - 44% below our estimate - integrates acquired banks so cost reductions and margin goals affect reported earnings.
Those are three of them. See all 29 potentially undervalued companies →
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com